Other languages Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Market Closed - Australian S.E. Other stock markets 01:59:20 2024-05-10 am EDT			5-day change	1st Jan Change
0.64 ^AUD	-1.54%		0.00%	+19.63%

07:03am	Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study	MT
May. 08	Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study	01:03am
Recce Pharmaceuticals Ltd.: Positive Wirksamkeitsdaten aus der Pilotstudie zu Lungeninfektionen am Murdoch Childrens Research Institute	May. 09
Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration	May. 08
Recce Pharmaceuticals Ltd.: Recce erhält Patentschutz für RECCE®-Antiinfektiva in China	May. 07
Recce Pharmaceuticals Obtains China Patent for Anti-Infectives	May. 07
Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis	Apr. 30
Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice	Apr. 17
Recce Pharmaceuticals Ltd.: Recce stellt 5.000 Dosen RECCE® 327 pro Woche nach der Guten Herstellungspraxis (GMP) her	Apr. 16
Recce Pharmaceuticals Ltd.: Recce Pharmaceuticals von der Innovationsagentur der Regierung des Vereinigten Königreichs für die Teilnahme an der AMR-Mission 2024 ausgewählt	Apr. 10
Recce Pharmaceuticals Ltd.: Recce Pharmaceuticals (ASX:RCE, FWB:R9Q) Business Update	Apr. 08
Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives	Apr. 04
Recce Pharmaceuticals Secures Israeli Patent for Anti-Infective Medication; Shares Rise 5%	Apr. 02
Recce Pharmaceuticals Secures Canadian Trademark for Antibiotic Medications	Mar. 20
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis	Mar. 19
Recce Pharmaceuticals Ltd.: Klinische Phase-I/II-Studie zur Schnellinfusion bei Harnwegsinfektionen/Urosepsis: Kohortenverabreichung wurde abgeschlossen	Mar. 15
Recce Pharmaceuticals Concludes Cohort Dosing in Synthetic Anti-Infectives Trial	Mar. 14
Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis	Mar. 14
Recce Pharmaceuticals Ltd.: Klinische Phase-I/II-Studie zur Schnellinfusion bei Harnwegsinfektionen/Urosepsis: Verabreichung an die nächste Kohorte hat begonnen	Mar. 12
Recce Pharmaceuticals Ltd.: Recce erhält F&E-Vorauszahlung in Höhe von 11,17 Mio. AUD	Mar. 08
Recce Pharmaceuticals Secures AU$11.2 Million R&D Advance; Shares Up 5%	Mar. 07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Other languages

Filters